Diabetic Retinopathy is the leading cause remained, leading to blindness and visual impairment in the middle age population. It can be extensively studied; taking biochemical pathways into consideration. It is unfortunate that there is still no cure for diabetic retinopathy but continual research leads to the development of novel therapeutic agents for the treatment of diabetic retinopathy. Spots or floating in your vision, blurred vision, impaired vision and vision loss are the most common symptoms seen.
Recent studies have revealed that laser photo coagulation can be the best treatment to destroy the excessive growth or leaking blood vessels in the retina.
The occurrence and progression rate of diabetic retinopathy was 38.3/1,000 man years and 21.1/1,000 man years, separately. Higher HbA(1c) (balanced HR [aHR] per 1% [10.9 mmol/mol] 1.36 [95% CI 1.28-1.45]), longer span of diabetes (aHR per 5 year period 1.26 [95% CI 1.17-1.35]), higher systolic circulatory pressure (aHR per +10 mmHg 1.01 [95% CI 1.00-1.02]) and higher body mass record (aHR per 1 kg/m(2) 1.05 [95% CI 1.00-1.09]) were connected with occurrence diabetic retinopathy. The relationship in the middle of HbA(1c) and occurrence diabetic retinopathy was direct; the relationship with span of diabetes expanded quickly somewhere around 5 and 10 years. Higher HbA(1c) was additionally connected with movement of diabetic retinopathy (aHR per 1% [10.9 mmol/mol] 1.66 [95% CI 1.41-1.96]). Observed frequency and Progression rates of diabetic retinopathy appeared to be lower than that in western japanese population. HbA(1c) was the main component connected with both rate and progression of diabetic retinopathy.